[
  {
    "ts": null,
    "headline": "Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial",
    "summary": "The data is the first head-to-head trial comparing the wildly popular medicines, and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market estimated to reach more than $150 billion annually by the next decade.  Zepbound helped nearly 25% more participants lose more than 15% of their weight compared to Wegovy, Lilly said on Sunday.",
    "url": "https://finnhub.io/api/news?id=b4ada219337ff0914bcfd59fb35d67160f2772d666d38f4486f5e2b509939623",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747001179,
      "headline": "Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial",
      "id": 134379239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The data is the first head-to-head trial comparing the wildly popular medicines, and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market estimated to reach more than $150 billion annually by the next decade.  Zepbound helped nearly 25% more participants lose more than 15% of their weight compared to Wegovy, Lilly said on Sunday.",
      "url": "https://finnhub.io/api/news?id=b4ada219337ff0914bcfd59fb35d67160f2772d666d38f4486f5e2b509939623"
    }
  },
  {
    "ts": null,
    "headline": "Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrati",
    "url": "https://finnhub.io/api/news?id=df39739f004eab72d79a25eed0a24120678a34d764551d5bf59ac44cc0ccd927",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747000860,
      "headline": "Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine",
      "id": 134379240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrati",
      "url": "https://finnhub.io/api/news?id=df39739f004eab72d79a25eed0a24120678a34d764551d5bf59ac44cc0ccd927"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of Medicine",
    "summary": "Eli Lilly and Company announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound , a dual GIP and GLP-1 receptor agonist, compared...",
    "url": "https://finnhub.io/api/news?id=0d0bd8084dcb6afdc30c379824b851105c389e1daa58d2bd6fbb8f3907ae4083",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746986460,
      "headline": "Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of Medicine",
      "id": 134376773,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound , a dual GIP and GLP-1 receptor agonist, compared...",
      "url": "https://finnhub.io/api/news?id=0d0bd8084dcb6afdc30c379824b851105c389e1daa58d2bd6fbb8f3907ae4083"
    }
  },
  {
    "ts": null,
    "headline": "Amphastar Pharmaceuticals: Navigating Through An Inflection Year",
    "summary": "Discover if Amphastar Pharmaceuticals is a buy after Q1 results and a stock dip.",
    "url": "https://finnhub.io/api/news?id=e151758f91430e4ce978cc41ff00fe9568c8491ec7f96b11f6ff1be490e3d9da",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746963131,
      "headline": "Amphastar Pharmaceuticals: Navigating Through An Inflection Year",
      "id": 134371653,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2046288144/image_2046288144.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover if Amphastar Pharmaceuticals is a buy after Q1 results and a stock dip.",
      "url": "https://finnhub.io/api/news?id=e151758f91430e4ce978cc41ff00fe9568c8491ec7f96b11f6ff1be490e3d9da"
    }
  },
  {
    "ts": null,
    "headline": "President Trump Just Announced Terrible News for Eli Lilly Investors",
    "summary": "President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks.  Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.  President Donald Trump's second term in office has been challenging for investors, at least so far.",
    "url": "https://finnhub.io/api/news?id=c4199e951a34380896753472a18617b64a49fe93375b70803fe7d894ed155024",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746962580,
      "headline": "President Trump Just Announced Terrible News for Eli Lilly Investors",
      "id": 134379241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks.  Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.  President Donald Trump's second term in office has been challenging for investors, at least so far.",
      "url": "https://finnhub.io/api/news?id=c4199e951a34380896753472a18617b64a49fe93375b70803fe7d894ed155024"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: These 2 Stocks Will Join the Trillion-Dollar Club by 2030",
    "summary": "Eli Lilly and Visa are closing in on a $1 trillion market cap.  There is a small, exclusive group of companies with market caps above $1 trillion.  Investors want to find companies that can perform well over the long run, even with market caps above $1 trillion.",
    "url": "https://finnhub.io/api/news?id=88b0b4f17b1ae8bea24e477c1adc474dedc9f4bcb7eba8161ba66ecfa82778cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746957900,
      "headline": "Prediction: These 2 Stocks Will Join the Trillion-Dollar Club by 2030",
      "id": 134379224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Visa are closing in on a $1 trillion market cap.  There is a small, exclusive group of companies with market caps above $1 trillion.  Investors want to find companies that can perform well over the long run, even with market caps above $1 trillion.",
      "url": "https://finnhub.io/api/news?id=88b0b4f17b1ae8bea24e477c1adc474dedc9f4bcb7eba8161ba66ecfa82778cd"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Charter Fund Q1 2025 Commentary",
    "summary": "Outperformance mainly resulted from stock selection in the consumer discretionary, health care and energy sectors.",
    "url": "https://finnhub.io/api/news?id=47c67780031ae9f1e8e62e138a47a2d4e20de28c34c16e13734a28f4ee43325b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746935100,
      "headline": "Invesco Charter Fund Q1 2025 Commentary",
      "id": 134369645,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442731840/image_1442731840.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Outperformance mainly resulted from stock selection in the consumer discretionary, health care and energy sectors.",
      "url": "https://finnhub.io/api/news?id=47c67780031ae9f1e8e62e138a47a2d4e20de28c34c16e13734a28f4ee43325b"
    }
  }
]